Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Perlman

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factorGail E Tomlinson, Norman E Breslow, Jeffrey Dome, et al.
Cancer|October 30, 2023
Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532Nicholas Evageliou, Lindsay A Renfro, James Geller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group StudyLinda Granowetter, Richard Womer, Meenakshi Devidas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study GroupPaul E Grundy, Norman E Breslow, Sierra Li, et al.
Cancer|November 7, 2023
Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5Daniel J Benedetti, Carly R Varela, Lindsay A Renfro, et al.
Cancer|February 24, 2024
Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2Daniel J Benedetti, Lindsay A Renfro, Ian Tfirn, et al.
JCI Insight|August 9, 2019
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumorMichael V Ortiz, Saima Ahmed, Melissa Burns, et al.
Pediatric Blood & Cancer|March 21, 2006
Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study GroupDaniel M Green, Cecilia A Cotton, Marcio Malogolowkin, et al.
Pediatric Blood & Cancer|June 1, 2007
Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study GroupMarcio Malogolowkin, Cecilia A Cotton, Daniel M Green, et al.
Nature Genetics|September 12, 2020
Author Correction: PGBD5 promotes site-specific oncogenic mutations in human tumorsAnton G Henssen, Richard Koche, Jiali Zhuang, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factorGail E Tomlinson, Norman E Breslow, Jeffrey Dome, et al.
Cancer|October 30, 2023
Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532Nicholas Evageliou, Lindsay A Renfro, James Geller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group StudyLinda Granowetter, Richard Womer, Meenakshi Devidas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study GroupPaul E Grundy, Norman E Breslow, Sierra Li, et al.
Cancer|November 7, 2023
Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5Daniel J Benedetti, Carly R Varela, Lindsay A Renfro, et al.
Cancer|February 24, 2024
Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2Daniel J Benedetti, Lindsay A Renfro, Ian Tfirn, et al.
JCI Insight|August 9, 2019
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumorMichael V Ortiz, Saima Ahmed, Melissa Burns, et al.
Pediatric Blood & Cancer|March 21, 2006
Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study GroupDaniel M Green, Cecilia A Cotton, Marcio Malogolowkin, et al.
Pediatric Blood & Cancer|June 1, 2007
Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study GroupMarcio Malogolowkin, Cecilia A Cotton, Daniel M Green, et al.
Nature Genetics|September 12, 2020
Author Correction: PGBD5 promotes site-specific oncogenic mutations in human tumorsAnton G Henssen, Richard Koche, Jiali Zhuang, et al.
Pageof 3